All In Biotech

Drug Trial Radar · NCT04379973

Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing:

Live Birth After Additional Tubal Flushing With Oil-based Contrast Versus no Additional Flushing: a Randomised, Multicentre, Parallel Group Pragmatic Trial in Infertile Women With at Least One Patent Tube at Hysterosalpingo-foam Sonography

Last checked: Nov 20, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 736 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

736

Planned (sponsor's estimate)

Start

May 25, 2021

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Dafne BalemansAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ten to 15 percent of couples in their reproductive lifetime face fertility problems which is defined by WHO as the absence of pregnancy after minimal 12 months of unprotected sexual intercourse. The three most frequent causes of subfertility are: sperm defects, ovulation disorders and tubal pathology. In order to exclude tubal pathology, tubal patency tests are performed under ultrasound guidance with foam (hysterosalpingo-foam sonography (Hyfosy)) or with contrast/water (hysterosalpingo-contrast sonography (Hycosy)). This trial will investigate whether tubal flushing with an oil-soluble contrast medium (OSCM) can increase the likelihood of a spontaneous conception after tubal patency testing with Hyfosy under ultrasound guidance compared to no additional flushing in a population of infertile women between 18 and 40 years of age with absence of pregnancy after 12 months of unprotected sexual intercourse or who have three cycles of donor insemination without pregnancy or three ovulatory ovulation induction cycles without pregnancy. The use of Lipiodol Ultra Fluide® is off-label in Hyfosy. This multicenter, randomised, open-label, comparative and pragmatic trial compares 2 arms which will be randomised 1:1: * Intervention group: Tubal flush with 5-10mL oil-soluble contrast medium (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy * Control group: No additional intervention after Hyfosy The study comprises a screening period of maximum 8 weeks (w-8 to d1), randomisation (w-8 to d1), a start study visit at which the Hyfosy is performed (d1) and a fertility treatment period of 6 months (d1-w26). If the woman is not pregnant at 6 months after Hyfosy, the follow-up will last till 12 months (w52). If the participant is pregnant at 6 months after Hyfosy, the follow-up will last till maximal 4 months after live birth or miscarriage. The primary endpoint is the occurrence of live birth, with the first day of the last menstrual cycle in which the patient conceives within 6 months after Hyfosy. Secondary endpoints consist of reproductive outcomes, gestational age at delivery, birth weight, neonatal mortality, major congenital anomaly, neonatal outcomes and thyroid function, pregnancy complications, number of complications during or immediately after the intervention, pain score of the Hyfosy and additional flush, thyroid function of the mother, general and disease-specific quality of life.

Conditions

  • Infertility, Female

Interventions

  • Lipiodol Ultra Fluide®Drug

    Tubal flush with 5-10mL oil-soluble contrast medium (OSCM) (Lipiodol Ultra Fluide®, Guerbet, France) immediately after Hyfosy. The use will be off-label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Live birthTime frame: Delivery

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Antwerp University Hospital

    Antwerp, Belgium

  • GZA Sint Augustinus

    Antwerp, Belgium

  • Imelda

    Bonheiden, Belgium

  • AZ Klina

    Brasschaat, Belgium

  • AZ Sint Jan Brugge

    Bruges, Belgium

  • CHIREC

    Brussels, Belgium

  • UCL Saint Luc

    Brussels, Belgium

  • UZ Brussel

    Brussels, Belgium

  • Ziekenhuis Oost Limburg

    Genk, Belgium

  • AZ Sint Lucas

    Ghent, Belgium

  • UZ Gent

    Ghent, Belgium

  • Hôpital Erasme

    Lennik, Belgium

  • UZ Leuven

    Leuven, Belgium

  • CHC Mont Légia

    Liège, Belgium

  • CHR Citadelle

    Liège, Belgium

  • AZ Turnhout

    Turnhout, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.